This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study
by Zacks Equity Research
Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.
Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
by Zacks Equity Research
Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.
Benitec Stock Up on Orphan Drug Status for BB-301 in EU
by Zacks Equity Research
Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
Key FDA Events to Watch Out for in Q1
by Zacks Equity Research
Two important regulatory events scheduled in the first quarter of 2017.
4 Profitable Stocks with Amazingly High Returns
by Zacks Equity Research
Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.
Novartis to Conduct Trial on Obese, Type II Diabetes Patients
by Zacks Equity Research
In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.
Coherus Offers Positive Phase III Data on Humira Biosimilar
by Zacks Equity Research
Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.
TESARO Varubi IV Gets Complete Response Letter in the U.S.
by Zacks Equity Research
TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.
TherapeuticsMD's Rejoice Study Data Published in Journal
by Zacks Equity Research
TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
by Zacks Equity Research
Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.
Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.
by Zacks Equity Research
Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.
Valeant Streamlines Portfolio with Skincare Brands Sale
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.
5 Underperformers of 2016: Turnaround Story in 2017?
by Zacks Equity Research
Based on strong fundamentals, strategic implementation, planned execution, and certain positive catalysts, these five stocks carry a huge upside potential and a high probability of outperforming the S&P 500 market index in the coming days.
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.
Zacks.com featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial
by Zacks Equity Research
Zacks.com featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
by Zacks Equity Research
Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.
Go Driehaus Way: 5 Momentum Picks
by Zacks Equity Research
Richard Driehaus, a pioneer in momentum investing, developed a strategy that has the potential to yield impressive returns.
Top Ranked Growth Stocks to Buy for January 6th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 6th:
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
Why Sucampo Pharmaceuticals (SCMP)Could Be an Impressive Growth Stock
by Zacks Equity Research
Sucampo Pharmaceuticals (SCMP) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective
Is Valeant (VRX) Fated for Terrible 2017 As Well?
by Zacks Equity Research
Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.